SUPPLEMENT

Q2 2020 — Reconciliation of Non-GAAP Financial Measures

Q2 2020PDF · 6 pages190 KB
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2020 	2019 	2020 	2019
Net Earnings, after tax- as reported 	$3,626 	$5,607 	$9,422 	$9,356
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,127 	1,118 	2,245 	2,248
Litigation expense, net 	613 	409 	733 	832
IPR&D 	6 	- 	6 	890
Restructuring related 	115 	142 	233 	232
Acquisition and Integration related ¹ 	29 	55 	(933) 	122
Unrealized (gains)/losses on securities 	(533) 	(148) 	(206) 	(306)
Medical Device Regulation 2 	37 	- 	51 	-
Other 	3 	(3) 	3 	-
Tax Adjustments
Tax impact on special item adjustments 3 	(253) 	(230) 	(520) 	(763)
Tax legislation and related impacts 	(324) 	- 	(434) 	-
Adjusted Net Earnings, after tax 	$4,446 	$6,950 	$10,600 	$12,611
Average shares outstanding (Diluted) 	2,665.5 	2,691.7 	2,671.0 	2,697.0
Adjusted net earnings per share (Diluted) 	$1.67 	$2.58 	$3.97 	$4.68
Operational adjusted net earnings per share (Diluted) 	$1.69 	$4.01
Notes:
1
2
3
Second Quarter 	Six Months Ended
Acquisition and integration related costs for the six months of 2020 primarily includes a $983M Contingent Consideration
reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously
registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework,
and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021.
The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of
on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its
Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing
performance.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.

-- 1 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
WW As Reported 	(7.0)% 	2.1% 	(33.9)% 	(10.8)%
U.S. 	1.3% 	5.8% 	(39.6)% 	(8.3)%
International 	(13.4)% 	(2.4)% 	(28.8)% 	(13.4)%
WW Currency 	(3.4) 	(1.8) 	(1.2) 	(1.8)
U.S. 	- 	- 	- 	-
International 	(6.0) 	(3.8) 	(2.4) 	(3.8)
WW Operational 	(3.6)% 	3.9% 	(32.7)% 	(9.0)%
U.S. 	1.3% 	5.8% 	(39.6)% 	(8.3)%
International 	(7.4)% 	1.4% 	(26.4)% 	(9.6)%
General Surgery
Advanced Sterilization Products 	0.1 	0.1
U.S. 	0.0 	0.0
International 	0.3 	0.2
Baby Care
Baby Center 	0.3 	0.0
U.S. 	0.7 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	0.0 	0.0 	0.1 	0.1
U.S. 	0.0 	0.0 	0.1 	0.0
International 	(0.1) 	0.1 	0.0 	0.0
WW Adjusted Operational 	(3.4)% 	3.9% 	(32.5)% 	(8.8)%
U.S. 	2.0% 	5.8% 	(39.5)% 	(8.1)%
International 	(7.5)% 	1.5% 	(26.1)% 	(9.4)%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SECOND QUARTER 2020 ACTUAL vs. 2019 ACTUAL
Segments
Consumer Health 	Pharmaceutical 	Medical Devices 	Total

-- 2 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
WW As Reported 	0.9% 	5.4% 	(21.1)% 	(3.8)%
U.S. 	10.8% 	7.2% 	(23.1)% 	(1.4)%
International 	(6.8)% 	3.2% 	(19.2)% 	(6.3)%
WW Currency 	(2.7) 	(1.6) 	(1.3) 	(1.6)
U.S. 	- 	- 	- 	-
International 	(4.9) 	(3.5) 	(2.4) 	(3.4)
WW Operational 	3.6% 	7.0% 	(19.8)% 	(2.2)%
U.S. 	10.8% 	7.2% 	(23.1)% 	(1.4)%
International 	(1.9)% 	6.7% 	(16.8)% 	(2.9)%
Skin Health / Beauty
Dr. Ci Labo - Japan 	(0.2) 	0.0
U.S. 	0.0 	0.0
International 	(0.4) 	(0.1)
General Surgery
Advanced Sterilization Products 	1.0 	0.4
U.S. 	1.1 	0.4
International 	0.9 	0.4
Baby Care
Baby Center 	0.3 	0.0
U.S. 	0.7 	0.1
International 	0.0 	0.0
All Other Acquisitions and Divestitures 	(0.1) 	0.1 	0.0 	0.0
U.S. 	0.0 	0.1 	0.0 	0.1
International 	(0.2) 	0.0 	0.0 	0.0
WW Adjusted Operational 	3.6% 	7.0% 	(18.8)% 	(1.7)%
U.S. 	11.5% 	7.2% 	(22.0)% 	(0.8)%
International 	(2.5)% 	6.7% 	(15.9)% 	(2.6)%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SIX MONTHS 2020 ACTUAL vs. 2019 ACTUAL
Segments
Consumer Health 	Pharmaceutical 	Medical Devices 	Total

-- 3 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019
Reported Income Before Tax by Segment 	$ 	32 	406 	4,514 	3,677 	(354) 	3,189 	(252) 	(231) 	3,940 	7,041
% to Sales 	1.0% 	11.5% 	42.0% 	34.9% 	-8.3% 	49.1% 	-1.4% 	-1.1% 	21.5% 	34.2%
Intangible asset amortization expense 	102 	124 	779 	754 	246 	240 	- 	- 	1,127 	1,118
In-process research and development 	- 	- 	- 	- 	6 	- 	- 	- 	6 	-
Litigation expense, net 	638 	172 	(58) 	26 	33 	211 	- 	- 	613 	409
Unrealized loss/(gain) on securities 	- 	1 	(522) 	(151) 	(11) 	2 	- 	- 	(533) 	(148)
Restructuring related 	20 	37 	21 	19 	74 	86 	- 	- 	115 	142
Acquisition and integration related 	- 	- 	10 	51 	19 	4 	- 	- 	29 	55
Medical Device Regulation 	- 	- 	- 	- 	37 	- 	- 	- 	37 	-
Other 	- 	- 	- 	- 	3 	(3) 	- 	- 	3 	(3)
Adjusted Income Before Tax by Segment 	$ 	792 	740 	4,744 	4,376 	53 	3,729 	(252) 	(231) 	5,337 	8,614
% to Sales 	24.0% 	20.9% 	44.1% 	41.6% 	1.2% 	57.5% 	-1.4% 	-1.1% 	29.1% 	41.9%
*Estimated as of 07/16/2020.
Q2 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 4 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019
Reported Income Before Tax by Segment 	$ 	802 	1,147 	8,348 	6,008 	1,671 	4,686 	(372) 	(378) 	10,449 	11,463
% to Sales 	11.6% 	16.7% 	38.1% 	28.9% 	16.4% 	36.2% 	-1.0% 	-0.9% 	26.8% 	28.2%
Intangible asset amortization expense 	202 	203 	1,550 	1,561 	493 	484 	- 	- 	2,245 	2,248
In-process research and development 	- 	- 	- 	890 	6 	- 	- 	- 	6 	890
Litigation expense, net 	638 	180 	35 	351 	60 	301 	- 	- 	733 	832
Unrealized loss/(gain) on securities 	1 	(3) 	(208) 	(294) 	1 	(9) 	- 	- 	(206) 	(306)
Restructuring related 	38 	44 	41 	44 	154 	144 	- 	- 	233 	232
Acquisition and integration related 	- 	- 	19 	90 	(952) 	32 	- 	- 	(933) 	122
Medical Device Regulation 	- 	- 	- 	- 	51 	- 	- 	- 	51 	-
Other 	- 	- 	- 	- 	3 	- 	- 	- 	3 	-
Adjusted Income Before Tax by Segment 	$ 	1,681 	1,571 	9,785 	8,650 	1,487 	5,638 	(372) 	(378) 	12,581 	15,481
% to Sales 	24.3% 	22.9% 	44.7% 	41.6% 	14.6% 	43.5% 	-1.0% 	-0.9% 	32.2% 	38.1%
*Estimated as of 07/16/2020.
Q2 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 5 of 6 --

Second Quarter 	Second Quarter
June 28, 2020
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related
Medical Device
Regulation 	Other
June 28, 2020
Non-GAAP
Cost of products sold 	6,579	$ 	(1,127) 	(22) 	(8) 	5,422
Selling, marketing and admin expenses 	4,993 	(6) 	4,987
Research and development expense 	2,707 	(5) 	(23) 	2,679
Other (Income) / Expense 	24 	- 	(613) 	(32) 	(24) 	533 	(3) 	(115)
In-process research and development 	6 	(6) 	-
Restructuring 	61 	(61) 	-
Provision for taxes on income 	314 	217 	123 	1 	22 	4 	(122) 	7 	324 	1 	891
Net Earnings 	3,626 	910 	490 	5 	93 	25 	(411) 	30 	(324) 	2 	4,446
Second Quarter 	Second Quarter
June 30, 2019
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related
Medical Device
Regulation 	Other
June 30, 2019
Non-GAAP
Cost of products sold 	6,940	$ 	(1,080) 	(38) 	- 	5,822
Other (Income) / Expense 	(1,683) 	(38) 	(409) 	(47) 	(55) 	148 	3 	(2,081)
Restructuring 	57 	(57) 	-
Provision for taxes on income 	1,434 	139 	67 	26 	5 	(31) 	24 	1,664
Net Earnings 	5,607 	979 	342 	116 	50 	(117) 	(27) 	6,950
Six Months 	Six Months
June 28, 2020
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related (1)
Medical Device
Regulation 	Other
June 28, 2020
Non-GAAP
Cost of products sold 	13,641	$ 	(2,245) 	(37) 	(22) 	11,337
Selling, marketing and admin expenses 	10,196 	(6) 	10,190
Research and development expense 	5,287 	(5) 	(23) 	5,259
Other (Income) / Expense 	(655) 	- 	(733) 	(77) 	938 	206 	(3) 	(324)
In-process research and development 	6 	(6) 	-
Restructuring 	119 	(119) 	-
Provision for taxes on income 	1,027 	363 	143 	1 	43 	7 	(47) 	9 	434 	1 	1,981
Net Earnings 	9,422 	1,882 	590 	5 	190 	(940) 	(159) 	42 	(434) 	2 	10,600
Six Months 	Six Months
June 30, 2019
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Acquisition
related
Medical Device
Regulation 	Other
June 30, 2019
Non-GAAP
Cost of products sold 	13,555	$ 	(2,210) 	(61) 	11,284
Other (Income) / Expense 	(1,705) 	(38) 	(832) 	(78) 	(122) 	306 	(2,469)
In-process research and development 	890 	(890) 	-
Restructuring 	93 	(93) 	-
Provision for taxes on income 	2,107 	423 	148 	187 	41 	12 	(64) 	16 	2,870
Net Earnings 	9,356 	1,825 	684 	703 	191 	110 	(242) 	(16) 	12,611
(1) Primarily includes a $983 million Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation
and related
impacts
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation
and related
impacts
Year to Date
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation
and related
impacts
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
Unrealized
(loss)/gain on
securities
Tax legislation
and related
impacts

-- 6 of 6 --